Clinical Trials Browser

capivasertib × 90 days × Clear all

NCT07287917 2026-03-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Phase 1/2 Recruiting

BreastDermatologic

Breast Neoplasms, Melanoma

NCT07294677 2026-03-04

CAVALRY

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT06982521 2026-03-03

ReDiscover-2

Phase 3 Recruiting

Breast Neoplasms

NCT07088913 2026-03-03

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants

Phase 1 Completed

Healthy Participants

NCT07281833 2026-02-27

CAPIcorn

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis, Disease Progression

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT07343960 2026-02-24

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

Phase 1 Recruiting

Moderate Hepatic Impairment

NCT03742102 2026-02-02

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04493853 2026-01-20

CAPItello-281

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT06635447 2026-01-13

CAPItrue

Phase 3 Recruiting

Breast Neoplasms, Disease Progression

NCT06764186 2026-01-13

CAPItana

Phase 3 Active not recruiting

Breast Neoplasms

NCT06613516 2025-12-24

CaptAin

Phase 2 Withdrawn

Breast Neoplasms

NCT03997123 2025-12-22

CAPItello-290

Phase 3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms